Skip to Main Content

Friday, March 22
7:00 a.m. PT / 10:00 a.m. ET

The failure of a closely watched Alzheimer’s clinical trial is a major blow to hopes for a new treatment for the disease. What experimental treatments are still being pursued? And what does the latest failure mean for the co-sponsor of the study, Biogen, which had so much at stake in the now-halted trial?

Register below to join STAT’s Sharon Begley, Matthew Herper, and Adam Feuerstein for this subscriber-only live chat, and to submit your questions in advance.